Examination of plasma zonulin levels in bipolar I disorder: a case–control study with follow-up

Simple item page
dc.contributor.authorAydın O.
dc.contributor.authorKocabaş T.
dc.contributor.authorSarandöl A.
dc.contributor.authorTaştan İ.
dc.contributor.authorOnur E.
dc.contributor.authorAydemir Ö.
dc.contributor.authorEsen-Danacı A.
dc.date.accessioned2024-07-22T08:07:03Z
dc.date.available2024-07-22T08:07:03Z
dc.date.issued2020
dc.description.abstractThere is an accumulation in studies which strive to reveal zonulin’s potential role in mental disorders. To date, one cross-sectional recent study examined zonulin in patients with bipolar disorders (BDs); however, its role still remains vague due to high fluctuation. Our aims are to determine plasma zonulin levels in exacerbation and treatment response periods, and to examine the associations between zonulin and symptom severity in BD. 30 patients with BD type I and 29 healthy controls participated in the current study. Socio-demographic form, Young Mania Rating Scale (YMRS), and Hamilton Depression Rating Scale (HAM-D) were administered. Enzyme-linked immune assay (ELISA) method was used to measure the plasma zonulin levels of the participants. The groups did not differ in plasma zonulin-level comparisons. Plasma zonulin did not alter between the exacerbation and treatment response periods of the patients. Besides, no associations were found between plasma zonulin-level and disease symptoms. Intestinal barrier integrity was not found to be altered among patients with BD type I. The lack of alterations in plasma zonulin level between different periods may be attributable to several factors. One possible factor might be the ELISA method which can detect other proteins (e.g., properdin) rather than zonulin. Therefore, it might fail to indicate direct observation of intestinal permeability. However, future study designs with more accurate estimation of zonulin in a larger sample may provide a different perspective on intestinal permeability’s possible role in BD etiology. © 2020, Springer-Verlag GmbH Austria, part of Springer Nature.
dc.identifier.DOI-ID10.1007/s00702-020-02234-7
dc.identifier.issn03009564
dc.identifier.urihttp://akademikarsiv.cbu.edu.tr:4000/handle/123456789/13801
dc.language.isoEnglish
dc.publisherSpringer
dc.subjectBipolar Disorder
dc.subjectCase-Control Studies
dc.subjectCross-Sectional Studies
dc.subjectFollow-Up Studies
dc.subjectHaptoglobins
dc.subjectHumans
dc.subjectProtein Precursors
dc.subjectprotein
dc.subjectunclassified drug
dc.subjectzonulin
dc.subjecthaptoglobin
dc.subjectprotein precursor
dc.subjectzonulin
dc.subjectadult
dc.subjectArticle
dc.subjectbipolar I disorder
dc.subjectbody mass
dc.subjectcase control study
dc.subjectclinical article
dc.subjectcomparative study
dc.subjectcontrolled study
dc.subjectcross-sectional study
dc.subjectdisease duration
dc.subjectdisease exacerbation
dc.subjectdisease severity
dc.subjectenzyme linked immunosorbent assay
dc.subjectfemale
dc.subjectfollow up
dc.subjectHamilton Depression Rating Scale
dc.subjecthuman
dc.subjecthypochondriasis
dc.subjectmale
dc.subjectpriority journal
dc.subjectprotein blood level
dc.subjecttobacco use
dc.subjecttreatment duration
dc.subjecttreatment response
dc.subjectYoung Mania Rating Scale
dc.subjectbipolar disorder
dc.titleExamination of plasma zonulin levels in bipolar I disorder: a case–control study with follow-up
dc.typeArticle

Files

Collections

Scopus Koleksiyonu